Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.

Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

Proceeds to accelerate expansion of global clinical research program and establish new production facilities to meet growing demand for the company's breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy).

TEL AVIV, Israel, -- Alpha Tau M...

The new Sealed Source and Device (SSD) approval enables the commencement of clinical trials in leading hospitals across the U.S. with the company’s breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy).  

Boston, MA, August 21st 2018 --...

 View article here

At the first Alpha Tau Medical Summit, international participants from leading cancer centers discussed the application of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) to various cancer types.

The Biomed Company Alpha Tau Medical, which developed a highly eff...

Following the promising preliminary clinical results, showing the ability of Alpha DaRT to effectively and safely destroy solid tumors, Alpha Tau Medical raises more capital than planned.

Alpha Tau Medical Ltd. has raised 20% more capital than planned for its Alpha DaRT...